Costoefectividad del régimen combinado de mirabegron/solifenacina en el tratamiento del síndrome de vejiga hiperactiva en Colombia

Resumen

Objetivo Evaluar la costoefectividad incremental del régimen combinado de mirabegron/solifenacina en comparación con el uso temprano de toxina botulínica, desde la perspectiva del sistema de salud colombiano, para el tratamiento de adultos con vejiga hiperactiva.

Métodos Se empleó un modelo de Markov en que se comparan dos secuencias de tratamiento, una con y otra sin mirabegron/solifenacina, para evaluar la costoefectividad en un horizonte temporal de cinco años. Debido a la perspectiva de análisis, sólo se tuvieron en cuenta los costos médicos directos. La eficacia del tratamiento evaluado y su comparador fue medida en términos de la reducción de episodios diarios de incontinencia y de la frecuencia de micciones. Los costos fueron expresados en pesos colombianos de 2019, y se aplicó una tasa de descuento de 5% tanto para desenlaces como para costos.

Resultados Para el caso base, el costo del tratamiento en la secuencia que incluye mirabegron/solifenacina fue mayor, pero generó un mayor número de años de vida ajustados por calidad, y así e obtuvo una razón de costoefectividad incremental de $13.637,184 si se considera el desenlace de reducción de episodios diarios de incontinencia de 50%, y de $29.313,848 si se considera el del 100%.

Conclusiones De acuerdo con los resultados de esta evaluación, para un horizonte de análisis de cinco años, la secuencia de tratamiento con mirabegron/solifenacina es una alternativa costoefectiva, si se considera un umbral de disposición a pagar de tres veces el producto interno bruto (PIB) per cápita.

Abstract

Aim To evaluate the incremental cost-effectiveness of the combined regimen of mirabegron/solifenacin compared with the early use of botulinum toxin, from the perspective of the Colombian health system, for the treatment of adults with overactive bladder.

Methods A Markov model comparing two treatment sequences, one with and one without mirabegron/solifenacin, was used to assess cost-effectiveness over a five-year period. Due to the perspective of the analysis, only direct medical costs were considered. The efficacy of the evaluated treatment and its comparator was measured in terms of the reduction in the daily incontinence episodes and the frequency of micturition. The costs were expressed in Colombian pesos of 2019, and a discount rate of 5% was applied for both outcomes and costs.

Results For the base case, the cost of the treatment in the sequence that includes mirabegron/solifenacin was higher, but it generated a greater number of quality-adjusted years of life, thus obtaining an incremental cost-effectiveness ratio of $13,637,184 when considering the outcome of 50% of reduction in the daily incontinence episodes, and $29,313,848 when considering 100%.

Conclusions According to the results of the present assessment, for a five-year period of analysi, the mirabegron/solifenacin treatment sequence is a cost-effective alternative when considering a threshold of willingness to pay three times the per capita gross domestic product (GDP).

Palabras Clave

costoefectividad - mirabegron - solifenacina - terapia combinada - onabotulinumtoxina A - vejiga urinaria hiperactiva

Keywords

cost-effectiveness - mirabegron - solifenacin - combined therapy - onabotulinum toxin A - overactive bladder

Publikationsverlauf

Eingereicht: 12. Januar 2021

Angenommen: 04. August 2021

Artikel online veröffentlicht:
22. Dezember 2021

• Referencias

• 1 White N, Iglesia CB. Overactive Bladder. Obstet Gynecol Clin North Am 2016; 43 (01) 59-68 DOI: 10.1016/j.ogc.2015.10.002.
• 2 Marcelissen T, Cornu JN, Antunes-Lopes T. et al. Management of idiopathic overactive bladder syndrome: What is the optimal strategy after failure of conservative treatment?. Eur Urol Focus 2018; 4 (05) 760-767 DOI: 10.1016/j.euf.2018.05.004.
• 3 Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive bladder syndrome: Evaluation and management. Curr Urol 2018; 11 (03) 117-125 DOI: 10.1159/000447205.
• 4 Truzzi JC, Gomes CM, Bezerra CA. et al. Overactive bladder - 18 years - Part I. Int Braz J Urol 2016; 42 (02) 188-198 DOI: 10.1590/S1677-5538.IBJU.2015.0365.
• 5 Plata M, Bravo-Balado A, Robledo D. et al. Prevalence of lower urinary tract symptoms and overactive bladder in men and women over 18 years old: The Colombian overactive bladder and lower urinary tract symptoms (COBaLT) study. Neurourol Urodyn 2019; 38 (01) 200-207 DOI: 10.1002/nau.23828.
• 6 Invima. Acta N° 1 de 2020. Comisión revisora. Sala especializada de moléculas nuevas, nuevas indicaciones y medicamentos biológicos. https://www.invima.gov.co/documents/20143/1675737/Acta-No-01-de-2020-SEMNNIMB.pdf Published 2020. Accessed June 1, 2020.
• 7 U.S. Food and Drug Administration (FDA). Summary products characteristicas: Mirabegron (Myrbetriq). https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202611s011lbl.pdf Published 2012. Accessed June 1, 2020.
• 8 Abrams P, Kelleher C, Staskin D. et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World J Urol 2017; 35 (05) 827-838 DOI: 10.1007/s00345-016-1908-1.
• 9 Herschorn S, Chapple CR, Abrams P. et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int 2017; 120 (04) 562-575 DOI: 10.1111/bju.13882.
• 10 Drake MJ, Chapple C, Esen AA. et al; BESIDE study investigators. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). Eur Urol 2016; 70 (01) 136-145 DOI: 10.1016/j.eururo.2016.02.030.
• 11 Peng L, Zeng X, Shen H, Luo D-Y. Efficacy and safety of combinations of mirabegron and solifenacin in patients with overactive bladder: a systematic review and meta-analysis. Int J Clin Exp Med 2019; 12 (02) 1355-1365
• 12 Instituto Nacional de Vigilancia de Medicamentos y Alimentos – Invima. Consulta de Registros Sanitarios. http://consultaregistro.invima.gov.co:8082/Consultas/consultas/consreg_encabcum.jsp Published 2019. Accessed May 27, 2018.
• 13 Aballéa S, Maman K, Thokagevistk K. et al. Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom. Clin Drug Investig 2015; 35 (02) 83-93 DOI: 10.1007/s40261-014-0240-z.
• 14 Bertapelle MP, Vottero M, Popolo GD. et al. Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System. World J Urol 2015; 33 (08) 1109-1117 DOI: 10.1007/s00345-014-1401-7.
• 15 Castaño J, Lopera A, Orozco J, Valencia J. Cost utility analysis of sacral neuromodulation versus botox a in the treatment of overactive bladder in Colombia. Value Health 2014; 17 (03) A294 DOI: 10.1016/j.jval.2014.03.1710.
• 16 Hakimi Z, Kelleher C, Aballéa S. et al. Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK. J Mark Access Health Policy 2018; 6 (01) 1438721 DOI: 10.1080/20016689.2018.1438721.
• 17 Instituto de Evaluación Tecnológica en Salud. Manual para la elaboración de evaluaciones económicas en Salud. Bogotá D.C.: IETS; 2014
• 18 Drake MJ, Nitti VW, Ginsberg DA. et al. Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis. BJU Int 2017; 120 (05) 611-622 DOI: 10.1111/bju.13945.
• 19 Kelleher C, Hakimi Z, Zur R. et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: A systematic review and network meta-analysis. Eur Urol 2018; 74 (03) 324-333 DOI: 10.1016/j.eururo.2018.03.020.
• 20 Allison SJ, Gibson W. Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience. Ther Adv Urol 2018; 10 (12) 411-419 DOI: 10.1177/1756287218801282.
• 21 Yeowell G, Smith P, Nazir J, Hakimi Z, Siddiqui E, Fatoye F. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open 2018; 8 (11) e021889 DOI: 10.1136/bmjopen-2018-021889.
• 22 Nitti VW, Ginsberg D, Sievert K-D. et al; 191622-096 Investigators. Durable efficacy and safety of long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: Final results of a 3.5-year study. J Urol 2016; 196 (03) 791-800 DOI: 10.1016/j.juro.2016.03.146.
• 23 Instituto de Seguros Sociales. Acuerdo 256 de 2001. Manual de tarifas de la Entidad Promotora de Salud EPS-ISS. https://lexsaludcolombia.files.wordpress.com/2010/10/tarifas-iss-2001.pdf. Published 2001. Accessed June 4, 2020.
• 24 Detalle licitación SECOP II: Sistema de Salud de la Policía Nacional. https://construyored.com/licitaciones/colombia/258726580 Published 2019. Accessed November 26, 2019.
• 25 Licitación pública: Subred integrada de Servicios de Salud Sur E.S.E. https://construyored.com/licitaciones/colombia/258726580 Published 2017. Accessed November 26, 2019.
• 26 Kato D, Tabuchi H, Uno S. Three-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post-marketing surveillance study. Low Urin Tract Symptoms 2019; 11 (02) O152-O161 DOI: 10.1111/luts.12237.
• 27 Ministerio de Salud y Protección Social (MSPS). Sismed - Sistema de información de precios de medicamentos. Reporte 2020. http://www.sispro.gov.co/recursosapp/app/Pages/Precios de Medicamentos - Circular 2 de 2012 Excel.aspx. Published 2021. Accessed April 10, 2021.